StreetInsider.com News Articles

Acrivon targets AML with oral CDK11 inhibitor, IND set for 2027

Tue, 20 Oct 2026 08:33:32 -0400

Acrivon Therapeutics (Nasdaq: ACRV) announced the advancement of ACR-7280, a potential first-in-class oral CDK11 inhibitor, as its next development candidate, with an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration planned for the first half of 2027. IND-enabling studies are currently underway, according to a company statement.

ACR-7280 was selected from multiple CDK11 inhibitor compounds identified through Acrivon's co-crystallography and AP3 platform. The company said its AP3-based indication finding identified acute myeloid leukemia (AML) as a predicted sensitive tumor type. In preclinical testing, ACR-7280 demonstrated complete tumor regression in in vivo AML xenograft models, including NPM1-mutated and

Acrivon targets AML with oral CDK11 inhibitor, IND set for 2027

Tue, 20 Oct 2026 08:33:32 -0400

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

Tue, 20 Oct 2026 08:30:00 -0400

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models

Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors

IND-enabling studies ongoing with IND submission on track for first half of 2027

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development,

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

Tue, 20 Oct 2026 08:30:00 -0400

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models

Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors

IND-enabling studies ongoing with IND submission on track for first half of 2027

Form 4 Acrivon Therapeutics, For: Oct 05 Filed by: Miller Mary

Wed, 07 Oct 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20261007/27161918.html

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, September 9, 2026, at 8:35 a.m. ET at the 2026 Cantor Global Healthcare Conference in New York, NY.

The live and archived webcast of this event can be accessed

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

Wed, 02 Sep 2026 08:00:00 -0400

The live and archived webcast of this event can be accessed

Acrivon Therapeutics names Michaela Levin as chief business officer

Mon, 31 Aug 2026 08:32:35 -0400

Acrivon Therapeutics (NASDAQ: ACRV) has appointed Michaela Levin, Ph.D., as chief business officer, effective Aug. 31, 2026, according to a company statement.

Levin most recently served as vice president of business development at Recursion, formerly Exscientia, where she led the acquisition of full rights to the ENPP1 inhibitor REV102 from Rallybio and negotiated multiple strategic term sheets. Before that, she was vice president of product intelligence and business development at Editas Medicine, where she negotiated licensing transactions including a Cas9 gene-editing technology license with Vertex Pharmaceuticals.

Earlier in her career, Levin held business development roles at Ovid Therapeutics, where she negotiated an

Acrivon Therapeutics names Michaela Levin as chief business officer

Mon, 31 Aug 2026 08:32:35 -0400

Acrivon Therapeutics (NASDAQ: ACRV) has appointed Michaela Levin, Ph.D., as chief business officer, effective Aug. 31, 2026, according to a company statement.

Earlier in her career, Levin held business development roles at Ovid Therapeutics, where she negotiated an

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Mon, 31 Aug 2026 08:30:00 -0400

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the appointment of Michaela Levin, Ph.D., as chief business officer, effective August 31, 2026. Dr. Levin comes with a solid, broad background in biotechnology business development, corporate strategy and transactional execution spanning mergers

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Mon, 31 Aug 2026 08:30:00 -0400

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy

Form 4 Acrivon Therapeutics, For: Aug 25 Filed by: Blume-Jensen Peter

Thu, 27 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260827/26990085.html

Form 4 Acrivon Therapeutics, For: Aug 25 Filed by: Blume-Jensen Peter

Thu, 27 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260827/26990085.html

Form 144 Acrivon Therapeutics, Filed by: Blume-Jensen Peter

Tue, 25 Aug 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260825/26976116.html

Form 144 Acrivon Therapeutics, Filed by: Blume-Jensen Peter

Tue, 25 Aug 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260825/26976116.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Peterson Katharine

Thu, 20 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26956269.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Peterson Katharine

Thu, 20 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260820/26956269.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Miller Mary

Thu, 20 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260820/26956246.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Miller Mary

Thu, 20 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260820/26956246.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Gamelin Erick

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956231.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Gamelin Erick

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956231.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Devroe Eric

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956224.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Devroe Eric

Thu, 20 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260820/26956224.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Blume-Jensen Peter

Thu, 20 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260820/26956207.html

Form 4 Acrivon Therapeutics, For: Aug 18 Filed by: Blume-Jensen Peter

Thu, 20 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260820/26956207.html